About Us
Our Mission & Values
Leadership Team
Board of Directors
Partners
Corporate Giving
Responsibility
Press Releases
Medicines
Science
Clinical Trials
Publications
Treatment Access
Patients & Caregivers
Our Commitment to Patients
Patient Voices
CKD with Hyperphosphatemia
IBS-C
Join Us
Working at Ardelyx
Benefits
Open Positions
Medical Professionals
Investors & Media
About Us
Our Mission & Values
Leadership Team
Board of Directors
Partners
Corporate Giving
Responsibility
Press Releases
Medicines
Science
Clinical Trials
Publications
Treatment Access
Patients & Caregivers
Our Commitment to Patients
Patient Voices
CKD with Hyperphosphatemia
IBS-C
Join Us
Working at Ardelyx
Benefits
Open Positions
Medical Professionals
Investors & Media
Publications
Disease Area
Hyperphosphatemia
IBS-C
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Filter
Tenapanor Improves Long-term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study
Kidney360
Long-Term Safety of Tenapanor in Patients with Irritable Bowel Syndrome with Constipation in the T3MPO-3 Study
Neurogastroenterology & Motility
Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na+/H+ Exchanger Isoform 3
ACS Medicinal Chemistry Letters
Efficacy of Tenapanor in Treating Patients with Irritable Bowel Syndrome with Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
The American Journal of Gastroenterology
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)
Journal of the American Society of Nephrology
Pages:
1
2
3
4
5
6
7
8
Load More
Sorry, nothing found in this query